sur The Vanguard Group, Inc. (isin : US12572Q1058)
The Vanguard Group Announces Stake in Avadel Pharmaceuticals
The Vanguard Group, Inc. has released its Form 8.3 disclosure under Rule 8.3 of the Irish Takeover Panel Act. This concerns its interest in Avadel Pharmaceuticals plc as of January 28, 2026. The form reveals that Vanguard holds a 5.99% stake in Avadel, with 5,833,370 ordinary shares valued at US$0.01 each.
The disclosure includes recent trade activities, detailing Vanguard's purchase of 2,236 shares at $21.54 each and sales of 4,284 and 31,704 shares at $21.54 and $21.55, respectively. No other cash-settled or stock-settled derivative transactions are noted. Additionally, Vanguard confirms that there are no indemnities or agreements that influence dealings with this stake.
R. H.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de The Vanguard Group, Inc.